Zosano Pharma Corporation (NASDAQ:ZSAN) recovered 75.66% of its value since hitting low of $0.452. The recent move of -11.58% drop pushed the stock to close at $0.79 when trading ended on Aug. 15, 2017. At recent session, the prices were hovering between $0.79 and $0.869. This company shares are 406.33% off its target price of $4 and the current market capitalization stands at $34.37M. The recent change has given its price a -39.24% deficit over SMA 50 and -77.56% deficit over its 52-week high. The stock witnessed -39.85% declines, -41.62% declines and -60.69% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ZSAN’s volatility during a week at 10.52% and during a month it has been found around 7.63%.

Zosano Pharma Corporation (ZSAN) Top Holders

Institutional investors currently hold around $8 million or 38.3% in ZSAN stock. Look at its top three institutional owners. Fmr Llc owns $1.6 million in Zosano Pharma Corporation, which represents roughly 4.64% of the company’s market cap and approximately 19.94% of the institutional ownership. Similar statistics are true for the second largest owner, Lombard Odier Asset Management (Usa) Corp, which owns 1,400,000 shares of the stock are valued at $1.26 million. The third largest holder is Opaleye Management Inc., which currently holds $1.1 million worth of this stock and that ownership represents nearly 3.2% of its market capitalization.

Zosano Pharma Corporation 13F Filings

At the end of 6/30/2017 reporting period, 13 institutional holders increased their position in Zosano Pharma Corporation (NASDAQ:ZSAN) by some 892,248 shares, 10 decreased positions by 1,687,258 and 9 held positions by 6,291,951. That puts total institutional holdings at 8,871,457 shares, according to SEC filings. The stock grabbed 3 new institutional investments totaling 31,727 shares while 7 institutional investors sold out their entire positions totaling 1,578,928 shares.

Zosano Pharma Corporation (NASDAQ:ZSAN) Insider Trades

Multiple company employees have indulged in significant insider trading. Zosano Pharma Corporation disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Interim CEO WALKER JOHN PETER has acquired 73,716 shares of Zosano Pharma Corporation (ZSAN) in trading session dated May. 25, 2017. These shares are worth $100,254 and were traded at $1.36 each. The SEC filing shows that WALKER JOHN PETER performed a purchase of 73,716 shares. The Interim CEO added these shares by way of transaction on May. 25, 2017. The company’s shares were assimilated at $1.36 per share worth to an investment of some $100,254 on account of WALKER JOHN PETER.

CFO and Chief Business Officer, Erbez Georgia, purchased 68,000 common shares of Zosano Pharma Corporation (ZSAN) in the open market. In a transaction dated May. 25, 2017, the shares were bought at an average price of $1.32, giving away a sum of $89,760. After this purchase, 115,750 common shares of ZSAN are directly owned by the insider, with total stake valued at $91,443.

In the transaction dated Feb. 13, 2017, the great number of shares disposed came courtesy the 10% Owner; BARRETT M JAMES disposed a total of 1,099,996 shares at an average price of $2.01, amounting to approximately $2,210,992. The insider now directly owns 952,814 shares worth $752,723.

Zosano Pharma Corporation (ZSAN) Analyst Guide

Not many analysts have released their opinion on Zosano Pharma Corporation (NASDAQ:ZSAN), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.

Previous article34 hedge funds sold their entire positions in Bridgepoint Education, Inc. (NYSE:BPI)
Next articleWindstream Holdings, Inc. (WIN) has rebounded -5% since its low of $1.88